[Edaily Reporter Kim Hyung-il ] Shinhan Investment Securities has assessed #Orum Therapeutics, Inc. as a global leader in the field of drug-acid conjugates (DACs)—a next-generation modality selected by global pharmaceutical companies Bristol-Myers Squibb (BMS) and Vertex. The firm projected that the likelihood of additional technology transfers would increase following the release of Phase 1 clinical data for ORM-6151—a leukemia treatment candidate currently being developed by BMS—and ahead of the clinical trial phase for ORM-1153, a treatment candidate for relapsed or refractory acute myeloid leukemia (AML) that the company is developing in-house.
On the 9th, Lee Ho-cheol, an analyst at Shinhan Investment Securities, explained that Orum Therapeutics, Inc. signed a technology transfer agreement with BMS for ORM-6151 (a new DAC drug) in 2023 and with Vertex for its DAC platform technology in 2024. He highlighted several areas to watch in the future: the planned release of Phase 1 clinical data for ORM-6151—currently under development by BMS—in 2027; the entry of ORM-1153, which the company is developing in-house, into clinical trials within the year; and the potential for additional technology transfers. DAC is a next-generation modality that applies target protein degradation (TPD) technology as the payload in antibody-drug conjugates (ADCs).
ORM-6151 is a blood cancer treatment that targets CD33 to degrade GSPT1. Orum Therapeutics, Inc. sold the asset to BMS in 2023 for an upfront payment of $100 million (approximately 134.1 billion won), with a total deal value of $180 million (approximately 241.3 billion won). The Phase 1 clinical trial cohorts for ORM-6151 have been expanded from the original monotherapy to include combination therapy with azacitidine or a three-drug regimen combining azacitidine and venetoclax. Analysts suggest this increases the drug’s potential to become a first-line treatment.
ORM-1153 is a newly developed blood cancer drug targeting CD123 to degrade GSPT1. The company received approval from the U.S. Food and Drug Administration (FDA) for its Phase 1 Investigational New Drug (IND) application in August of this year and aims to administer the first dose to a patient by the end of the year. Preclinical studies in patients with TP53 mutations—a group in which response rates to existing treatments drop sharply—also confirmed the same level of efficacy.
The analyst projected that the success of the Phase 1 clinical trials for ORM-6151 and ORM-1153 would establish the world’s first human proof of concept (Human PoC) for the DAC platform. He also anticipated that the success of these drugs’ Phase 1 trials would increase the visibility of subsequent technology transfers and milestone payments.
Meanwhile, ORM-5029 (a HER2-targeted DAC), whose clinical trial was halted in April 2025, was analyzed as having been caused by the low stability of the VC linker in the bloodstream, rather than limitations inherent to the modality itself. ORM-6151 and ORM-1153, which have now entered clinical trials, utilize a beta-glucuronide linker to minimize payload release in the bloodstream.
On the 9th, Lee Ho-cheol, an analyst at Shinhan Investment Securities, explained that Orum Therapeutics, Inc. signed a technology transfer agreement with BMS for ORM-6151 (a new DAC drug) in 2023 and with Vertex for its DAC platform technology in 2024. He highlighted several areas to watch in the future: the planned release of Phase 1 clinical data for ORM-6151—currently under development by BMS—in 2027; the entry of ORM-1153, which the company is developing in-house, into clinical trials within the year; and the potential for additional technology transfers. DAC is a next-generation modality that applies target protein degradation (TPD) technology as the payload in antibody-drug conjugates (ADCs).
ORM-6151 is a blood cancer treatment that targets CD33 to degrade GSPT1. Orum Therapeutics, Inc. sold the asset to BMS in 2023 for an upfront payment of $100 million (approximately 134.1 billion won), with a total deal value of $180 million (approximately 241.3 billion won). The Phase 1 clinical trial cohorts for ORM-6151 have been expanded from the original monotherapy to include combination therapy with azacitidine or a three-drug regimen combining azacitidine and venetoclax. Analysts suggest this increases the drug’s potential to become a first-line treatment.
ORM-1153 is a newly developed blood cancer drug targeting CD123 to degrade GSPT1. The company received approval from the U.S. Food and Drug Administration (FDA) for its Phase 1 Investigational New Drug (IND) application in August of this year and aims to administer the first dose to a patient by the end of the year. Preclinical studies in patients with TP53 mutations—a group in which response rates to existing treatments drop sharply—also confirmed the same level of efficacy.
The analyst projected that the success of the Phase 1 clinical trials for ORM-6151 and ORM-1153 would establish the world’s first human proof of concept (Human PoC) for the DAC platform. He also anticipated that the success of these drugs’ Phase 1 trials would increase the visibility of subsequent technology transfers and milestone payments.
Meanwhile, ORM-5029 (a HER2-targeted DAC), whose clinical trial was halted in April 2025, was analyzed as having been caused by the low stability of the VC linker in the bloodstream, rather than limitations inherent to the modality itself. ORM-6151 and ORM-1153, which have now entered clinical trials, utilize a beta-glucuronide linker to minimize payload release in the bloodstream.
